Jim Simons Abeona Therapeutics Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 134,278 shares of ABEO stock, worth $832,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,278

Previous 503,293 73.32%

Holding current value

$832,523

Previous $2.13 Million 60.24%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.12 - $6.32 $1.52 Million - $2.33 Million	-369,015 Reduced 73.32%	134,278 $848,000
Q2 2024 Aug 09, 2024	BUY	$3.17 - $8.05 $1.36 Million - $3.46 Million	429,456 Added 581.63%	503,293 $2.13 Million
Q1 2024 May 13, 2024	SELL	$4.07 - $8.68 $441,822 - $942,266	-108,556 Reduced 59.52%	73,837 $535,000
Q4 2023 Feb 13, 2024	BUY	$3.71 - $5.14 $562,272 - $778,997	151,556 Added 491.47%	182,393 $914,000
Q3 2023 Nov 14, 2023	SELL	$2.98 - $4.43 $8,046 - $11,961	-2,700 Reduced 8.05%	30,837 $130,000
Q2 2023 Aug 11, 2023	SELL	$2.76 - $5.27 $9,108 - $17,391	-3,300 Reduced 8.96%	33,537 $135,000
Q1 2023 May 12, 2023	SELL	$2.25 - $3.27 $58,050 - $84,366	-25,800 Reduced 41.19%	36,837 $104,000
Q4 2022 Feb 13, 2023	SELL	$2.4 - $5.65 $13,200 - $31,075	-5,500 Reduced 8.07%	62,637 $193,000
Q3 2022 Nov 14, 2022	BUY	$2.79 - $5.56 $190,102 - $378,841	68,137 New	68,137 $207,000

Others Institutions Holding ABEO

# of Institutions

Shares Held

26.9M

Call Options Held

614K

Put Options Held

45K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $36.9M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account